OnKure Therapeutics Past Earnings Performance
Past criteria checks 0/6
OnKure Therapeutics's earnings have been declining at an average annual rate of -32%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-32.0%
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How OnKure Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -45 | 7 | 38 |
| 30 Jun 24 | 0 | -42 | 7 | 36 |
| 31 Mar 24 | 0 | -36 | 5 | 33 |
| 31 Dec 23 | 0 | -35 | 5 | 32 |
Quality Earnings: OKUR is currently unprofitable.
Growing Profit Margin: OKUR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if OKUR's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare OKUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OKUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: OKUR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.